1346556-73-7

Basic information

• Product Name: 7-Boc-7-azaspiro[3.5]nona...
• Synonyms: 7-Boc-7-azaspiro[3.5]nonane-2-carbaldehyde;tert-butyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate;7-Boc-7-azaspiro[3.5]nonane-2-carbaldehyde - A7204
• CAS NO: 1346556-73-7
• Molecular Formula: C₁₄H₂₃NO₃
• Molecular Weight: 253.34
• Mol File: 1346556-73-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 353.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• PKA: -1.04±0.40(Predicted)
• CAS DataBase Reference: 7-Boc-7-azaspiro[3.5]nona...(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Boc-7-azaspiro[3.5]nona...(1346556-73-7)
• EPA Substance Registry System: 7-Boc-7-azaspiro[3.5]nona...(1346556-73-7)

Safety Data

• Hazardous Substances Data: 1346556-73-7(Hazardous Substances Data)

Usage

General Description

7-Boc-7-azaspiro[3.5]nona-1,3,5-triene-3-carboxylic acid is a chemical compound with a unique spirocyclic structure containing a bicyclic ring system with a nitrogen atom. The compound is commonly used in organic synthesis as a building block for creating complex molecules and drug candidates. The Boc (tert-butyloxycarbonyl) protective group plays a crucial role in the compound's reactivity and stability, allowing for selective functionalization and manipulation of its chemical properties. Its versatile nature and potential for structural modification make it a valuable tool in the development of new pharmaceuticals and biologically active molecules. Additionally, its spirocyclic framework makes it an interesting target for the synthesis of novel heterocyclic compounds with potential biological activities.

Upstream product

• 203661-69-2 tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate 
• 1356476-38-4 tert-butyl 2-methylene-7-azaspiro[3.5]nonane-7-carboxylate 

Downstream Products

• 1346556-74-8 C₂₇H₃₁F₃N₂O₃ 
• 1346556-75-9 C₂₇H₂₈F₃N₅O₂ 
• 1356476-76-0 C₂₇H₃₃F₃N₂O₃ 
• 1416173-72-2 tert-butyl 2-{3-[4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416173-68-6 tert-butyl 2-{3-[2-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416173-86-8 tert-butyl 2-{3-[3-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416175-45-5 propan-2-yl 2-{3-[4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416175-50-2 propan-2-yl 2-{3-[3-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416175-52-4 1-methylcyclopropyl 2-{3-[3-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416175-71-7 cyclopentyl 2-{3-[3-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416175-72-8 2,2-dimethylpropyl 2-{3-[3-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane-7-carboxylate 
• 1416175-24-0 7-(5-ethylpyrimidin-2-yl)-2-{3-[4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane 
• 1416175-32-0 7-(5-ethylpyrimidin-2-yl)-2-{3-[2-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane 
• 1416175-33-1 7-(5-ethylpyrimidin-2-yl)-2-{3-[3-fluoro-4-(methanesulfonyl)phenoxy]propyl}-7-azaspiro[3.5]nonane 

Relevant articles and documents

Ring derivative of inhibitor for bromodomains in bromodomain and extra-teminal domain (BET) family, and preparation method and pharmaceutical application of ring derivative

The invention relates to a compound as shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or an eutectic crystal thereof, an intermediate and a preparation method of the compound or the stereoisomer, the deuterated compound, the solvate, the prodrug, the metabolite, the pharmaceutically acceptable salt orthe eutectic crystal thereof, and application of the compound or the stereoisomer, the deuterated compound, the solvate, the prodrug, the metabolite, the pharmaceutically acceptable salt or the eutectic crystal thereof in inhibiting or degrading diseases related to the bromodomains in the BET family. The formula (I) is B-L-K.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists

The design and synthesis of a novel class of 7-azaspiro[3.5]nonane GPR119 agonists are described. In this series, optimization of the right piperidine N-capping group (R2) and the left aryl group (R3) led to the identification of compound 54g as a potent GPR119 agonist. Compound 54g showed a desirable PK profile in Sprague-Dawley (SD) rats and a favorable glucose lowering effect in diabetic rats.